Polyrizon Ltd. Announces Successful Preclinical Results for Intranasal PL-14 Allergy Blocker, Paving Way for Clinical Trials
Reuters
Sep 12
<a href="https://laohu8.com/S/PLRZ">Polyrizon Ltd.</a> Announces Successful Preclinical Results for Intranasal PL-14 Allergy Blocker, Paving Way for Clinical Trials
Polyrizon Ltd. (Nasdaq: PLRZ) has announced promising preclinical results for its PL-14 Allergy Blocker, as part of its Capture & Contain (C&C) platform. Conducted in collaboration with the University of Parma, the study demonstrated targeted deposition in the nasal vestibule, a critical site for early allergen contact. The PL-14 formulation exhibited over 60% deposition in this region, supporting its potential as a preventive treatment for allergic rhinitis. The study, led by Professor Fabio Sonvico, utilized a validated silicone-based human nasal cast to assess the spray deposition profile. Polyrizon plans to continue preclinical efforts and move towards clinical trials. The global allergen blocker market is projected to grow, with an expected value increase from USD 0.14 billion in 2024 to USD 0.21 billion by 2033.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9528040-en) on September 12, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.